Literature DB >> 26700590

α1-Adrenoceptors relate Ca(2+) modulation and protein secretions in rat lacrimal gland.

Chika Ikeda-Kurosawa1, Hironori Higashio, Masato Nakano, Masatoshi Okubo, Yoh-Ichi Satoh, Daijiro Kurosaka, Tomoyuki Saino.   

Abstract

Noradrenaline (NA) is a catecholamine with multiple roles including as a hormone and a neurotransmitter. Cellular secretory activities are enhanced by adrenergic stimuli as well as by cholinergic stimuli. The present study aimed to determine which adrenoceptors play a role in controlling intracellular calcium ion ([Ca(2+)]i) level in acinar cells of rat lacrimal glands. Expression of mRNA for adrenoceptor subtypes in the acinar cells was assessed using RT-PCR. All types except α2c, β1, and β3 were detected. NA induced a [Ca(2+)]i increase with a biphasic pattern in the acinar cells. Removal of extracellular Ca(2+) and use of Ca(2+)-channel blockers did not inhibit the NA-induced [Ca(2+)]i increases. In contrast, U73122 and suramin almost blocked these increases. The α1-adrenoceptor agonist phenylephrine induced a strong increase in [Ca(2+)]i. However, clonidine and isoproterenol failed to induce a [Ca(2+)]i increase. The peroxidase activity was quantified as a measure of mucin secretion. Ca(2+)-dependent exocytotic secretion of peroxidase was detected in rat lacrimal glands. The RT-PCR results showed that MUC1, MUC4, MUC5AC, MUC5B, and MUC16 were expressed in acinar cells. These findings indicated that NA activates α1-adrenoceptors, which were found to be the main receptors in Ca(2+)-related cell homeostasis and protein (including mucin) secretion in lacrimal glands.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26700590     DOI: 10.2220/biomedres.36.357

Source DB:  PubMed          Journal:  Biomed Res        ISSN: 0388-6107            Impact factor:   1.203


  1 in total

1.  Alpha-Adrenergic Agonists Stimulate Fluid Secretion in Lacrimal Gland Ducts.

Authors:  Dóra Szarka; Gréta Elekes; Orsolya Berczeli; Eszter Vizvári; László Szalay; Chuanqing Ding; László Tálosi; Edit Tóth-Molnár
Journal:  Invest Ophthalmol Vis Sci       Date:  2020-12-01       Impact factor: 4.799

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.